SUN PHARMACEUTICAL INDUSTRIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,516 INR | +0.34% |
|
+0.61% | +20.37% |
| Sales 2024 | 48TCr 580.6Cr | Sales 2025 * | 53TCr 636.42Cr | Capitalization | 3,63700Cr 4.35TCr |
|---|---|---|---|---|---|
| Net income 2024 | 9.58TCr 114.65Cr | Net income 2025 * | 11TCr 131.98Cr | EV / Sales 2024 | 8.02 x |
| Net cash position 2024 * | 9.8TCr 117.3Cr | Net cash position 2025 * | 18TCr 219.16Cr | EV / Sales 2025 * | 6.5 x |
| P/E ratio 2024 |
40.6
x | P/E ratio 2025 * |
33
x | Employees | 41,000 |
| Yield 2024 * |
0.82% | Yield 2025 * |
0.93% | Free-Float | 45.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sun Pharmaceutical Industries Ltd.
More recommendations
More press releases
More news
| 1 day | +0.34% | ||
| 1 week | +0.61% | ||
| Current month | +3.85% | ||
| 1 month | -0.75% | ||
| 3 months | -2.08% | ||
| 6 months | +22.68% | ||
| Current year | +20.37% |
1 week
1 495.85
1 525.00
1 month
1 377.201 564.00
Current year
1 257.151 638.85
1 year
977.301 638.85
3 years
652.701 638.85
5 years
312.001 638.85
10 years
312.001 638.85
| Managers | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Founder | 68 | 01/82/01 | |
| Director of Finance/CFO | - | 19/17/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 01/82/01 | |
Rama Bijapurkar
BRD | Director/Board Member | 67 | 21/21/21 |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15/23/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.72% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 1,516 | +0.34% | 937,490 |
| 13/24/13 | 1,511 | +0.26% | 1,412,477 |
| 12/24/12 | 1,507 | +0.47% | 994,784 |
| 11/24/11 | 1,500 | -0.88% | 1,441,589 |
| 10/24/10 | 1,513 | +0.41% | 1,433,942 |
Delayed Quote NSE India S.E., June 14, 2024 at 05:13 pm IST
More quotes
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
1,516
INR
Average target price
1,619
INR
Spread / Average Target
+6.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.37% | 4.35TCr | |
| +19.44% | 2.18TCr | |
| +17.85% | 1.54TCr | |
| +25.55% | 1.51TCr | |
| +60.99% | 1.34TCr | |
| -0.05% | 678.76Cr | |
| -15.02% | 638.15Cr | |
| -8.87% | 572.55Cr | |
| +8.17% | 532.14Cr | |
| +26.36% | 458.27Cr |
- Stock Market
- Equities
- SUNPHARMA Stock
